Ineffectiveness of neurokinin-1 antagonist in acute migraine: A crossover study

Cephalalgia

Volumn 17, Issue 7, 1997, Pages 785-790

  Goldstein, D J ^a,b,c   Wang, O ^a   Saper, J R ^e   Stoltz, R ^d   Silberstein, S D ^f   Mathew, N T ^g  

^a ELI LILLY AND COMPANY   (United States)

^b INDIANA UNIVERSITY   (United States)

^c METHODIST HOSPITAL   (United States)

^d GFI Pharmaceutical Services Inc   (United States)

^e Michigan Head Pain and Neurological Institute   (United States)

^f Germantown Hospital   (United States)

^g Houston Headache Clinic   (United States)

Author keywords

Lanepitant; Migraine; Neurokinin 1 antagonist

Indexed keywords

LANEPITANT; NEUROKININ 1 RECEPTOR ANTAGONIST;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; MIGRAINE; ORAL DRUG ADMINISTRATION; PAIN ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; TREATMENT PLANNING;

EID: 0030834838     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-2982.1997.1707785.x     Document Type: Article

References (25)

1. Celentano DD, Stewart WF, Lipton RB, Reed ML. Medication use and disability among migraineurs: national probability sample. Headache 1992;32:223-8
2. Lipton RB, Stewart WF, Celentano DD, Reed ML. Undiagnosed migraine: a comparison of symptom-based and physician diagnosis. Arch Intern Med 1992;152:1273-8
3. Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalescence of migraine headache in the United States: relation to age, income, race, and other sociodemographic factors. JAMA 1992;267:64-9
4. Headache Classification Committee of the International Headache Society. Classification and diagnosis criteria for headache disorders, cranial neuralgias, and facial pain. Cephalalgia 1988;8 Suppl 7:1-96
5. de Lissovoy G, Lazarus SS. The economic cost of migraine. Neurology 1994;44 Suppl 4:S56-S62
6. Blau JN. Migraine: a vasomotor instability of the meningeal circulation. Lancet 1978;2:1136-9
7. Moskowitz MA, Reinhard J Jr, Romero J. Neurotransmitters and the fifth cranial nerve: is there a relation to the headache phase of migraine? Lancet 1979;2:883-5
8. Mayberg M, Langer RS, Zervas NT. Perivascular meningeal projections from cat trigeminal ganglia; possible pathway for vascular headaches in man. Science 1981;213:228-30
9. Pay BS, Wolff HG. Experimental studies on headache: painsensitive structures in the head and their significance in headache. Arch Surg 1940;41:813-56
10. Goadsby PJ, Zagami AS, Lambert GA. Neural processing of craniovascular pain; a synthesis of the central structures involved in migraine. Headache 1991;31:365-71
11. Nozaki K, Boccalini P, Moskowitz MA. Expression of c-fos-like immunoreacrivity in brainstem after meningeal irritation by blood in subarachnoid space. Neuroscience 1992;49:669-80
12. Nozaki K, Moskowitz MA, Boccalini P. CP-93-129, sumatriptan dihydroergotamine block c-fos expression within rat trigeminal nucleus caudalis caused by chemical stimulation of the meninges. Br J Pharmacol 1992;106:409-15
13. Moskowitz MA, Nozaki K, Kraig RP. Neocortical spreading depression provokes the expression of c-fos protein-like immunoreactivity within trigeminal nuclear caudalis via trigeminovascular mechanism. J Neurosci 1993;13:1167-77
14. Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol 1988;23:193-6
15. Markowitz S, Saito K, Moskowitz MA. Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not brain. J Neurosci 1987;7:4129-36
16. Dimitriadou V, Buzzi MG, Moskowitz MA, Theoharides TC. Trigeminal sensory fiber stimulation induces morphological changes reflecting secretion in rat dura mater mast cells. Neuroscience 1991;44:97-112
17. Dimitriadou V, Buzzi MG, Theoharides TC, Moskowitz MA. Ultrastructure evidence for neurologenically mediated changes in blood vessels of the rat dura mater and tongue following antidromic trigeminal stimulation. Neuroscience 1992;48:187-203
18. Brain SD, Williams TJ. Inflammatory oedema induced by synergism between calcitonin gene-related peptide (CGRP) and mediators of increased vasculary permeability. Br J Pharmacol 1985;86:855-60
19. Le Greves P, Nyberg F, Terenius L, Hokfelt T. Calcitonin generelated peptide is a potent inhibitor of substance P degradation. Eur J Pharmacol 1985;115:309-11
20. Schiable H, Hope PJ, Lang CW, Duggan AW. Calcitonin gene-related peptide causes intraspinal spreading of substance P released by peripheral stimulation. Eur J Neurosci 1992;4:750-7
21. Gitter BD, Bruns RF, Howbert JJ, Waters DC, Threlkeld PG, Cox LM, et al. Pharmacological characterization of LY303870: A novel, potent and selective nonpeptide substance P (neurokinin-1) receptor antagonist. J Pharmacol Exp Ther 1995;275:737-44
22. Buzzi MG, Moskowitz MA. The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br J Pharmacol 1990;99:202-6
23. Hipskind PA, Howbert JJ, Bruns RF, Cho SSY, Crowell TA, Foreman MM, et al. 3-Aryl-l,2-diacetamidopropane derivatives as novel and potent NK-1 receptor antagonists. J Med Chemy 1996;39:736-748
24. Diener HC, Hartung, Gobel, Beckmann, Langohr, Klapper, et al. Substance-P antagonist RPR 100893-201 is not effective in human migraine attacks. 6th International Headache Research Seminar, November 1995:63
25. Patrick WM, DeMaster E, Malhotra, et al. Science 1995;268:1629-32